Table 3.
Clinical trials (completed and ongoing) involving nanoparticles for cancer immunotherapy.
| S. No | Clinical Trial | Cancer Type | Therapeutic Intervention | Clinical Trial ID |
|---|---|---|---|---|
| 1 | A study to evaluate/tolerability of immune-therapy combinations in participation with TNBC or gynaecologic malignancies (Completed) | TNBC and Ovarian cancer | Etrumadenant (antagonist of immunomodulatory checkpoint molecules adenosine A2A and A2B receptors), Eganelisib (IPI-549, phosphoinositide 3-kinase inhibitor), PEGylated liposomal doxorubicin (PLD), albumin nanoparticle-bound paclitaxel (NP) | NCT03719326 |
| 2 | Neoadjuvant LDRT combined with Durvalumab in potentially resectable stage III NSCLC (Ongoing) | Stage III NSCLC | Durvalumab (immune checkpoint inhibitor antibody), Albumin nanoparticle-bound paclitaxel along with low-dose radiation therapy | NCT05157542 |
| 3 | Dose escalation study of immunomodulatory nanoparticles (Ongoing) | Advanced solid tumours | PRECIOUS-01 (invariant natural killer T cell activator threitolceramide-6 and New York Esophageal Squamous Cell Carcinoma-1 cancer-testis antigen peptides encapsulated in PLGA nanoparticle) | NCT04751786 |
| 4 | A pilot study of neoadjuvant chemotherapy with or without Camrelizumab for locally advanced gastric cancer (Ongoing) | Gastric cancer | Camrelizumab (anti-PD1) and chemotherapy with albumin nanoparticle-bound paclitaxel and oxaliplatin | NCT05101616 |
| 5 | NBTXR3, Radiation Therapy, and Pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell cancer (Ongoing) | Metastatic head and neck squamous cell carcinoma and recurrent head and neck squamous cell carcinoma | Hafnium oxide containing nano- particles (NBTXR3) with hypo-fractionated radiation therapy and Pembrolizumab (anti-PD1 humanized antibody) with Stereotactic body radiation therapy | NCT04862455 |
| 6 | Radiation therapy to the usual treatment (Immunotherapy with or without chemotherapy) for Stage IV non-small cell lung cancer patients who are PD-L1 negative (Ongoing) | Advanced lung adenocarcinoma, Advanced lung adenosquamous carcinoma, Advanced and metastatic lung NSCC (Stages IIIB/IIIC/IV/IVA/IVB), Metastatic lung adeno-carcinoma, Metastatic lung adeno-squamous carcinoma, lung cancer AJCC v8 | Carboplatin, Ipilimumab (CTLA4 targeting antibody), albumin nanoparticle-bound paclitaxel, Nivolumab (anti-PD1), Paclitaxel, Pembrolizumab, Pemetrexed along with Stereotactic body radiation therapy | NCT04929041 |
| 7 | Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab before surgery for the treatment of in resectable/borderline resectable primary pancreatic cancer (Ongoing) | Borderline resectable pancreatic adeno-carcinoma, Resectable pancreatic adeno-carcinoma (IA/IB/IIA/IIB) pancreatic cancer AJCC v8 | Durvalumab, Gemcitabine, albumin nanoparticle-bound paclitaxel, Oleclumab (anti-CD73) | NCT04940286 |
| 8 | Combination with chemotherapy for the treatment of advanced solid tumours involving the abdomen or thorax (Ongoing) | Advanced breast carcinoma, Advanced endometrial carcinoma, Advanced fallopian tube carcinoma, Advanced hepatocellular carcinoma, Advanced malignant abdominal neoplasm, Advanced malignant female reproductive system neoplasm, Advanced malignant thoracic neoplasm, Advanced ovarian carcinoma, Advanced primary peritoneal carcinoma, Advanced renal cell carcinoma | Atezolizumab (anti-PD1), Cabozantinib S-malate (tyrosine kinase inhibitor), albumin nanoparticle-bound paclitaxel | NCT05092373 |
| 9 | Durvalumab in combination with chemotherapy in treating patients with advanced solid tumours (Ongoing) | Locally advanced malignant solid neoplasm, Metastatic malignant solid neoplasm, Unresectable malignant solid neoplasm | Capecitabine, Carboplatin, Durvalumab, Gemcitabine hydrochloride, Paclitaxel, albumin nanoparticle-bound paclitaxel, PEGylated liposomal doxorubicin hydrochloride | NCT03907475 |
| 10 | Addition of anticancer drug, ZEN003694 (ZEN-3694) and PD-1 inhibitor (Pembrolizumab) to standard chemo-therapy (Nab-Paclitaxel) treatment in patients with advanced Triple-Negative Breast Cancer (TNBC) (Ongoing) | Anatomic stage III/IV breast cancer AJCC, Locally advanced TNBC, Metastatic TNBC, Unresectable TNBC | BET Bromodomain inhibitor ZEN-3694, albumin nanoparticle-bound paclitaxel, Pembrolizumab | NCT05422794 |
| 11 | Pembro + Chemo in brain mets (Ongoing) | Lung cancer, Lung cancer metastatic, Brain cancer, Cancer | Pembrolizumab, Paclitaxel, Pemetrexed, Carboplatin, albumin nanoparticle-bound paclitaxel | NCT04964960 |
| 12 | Atezolizumab with chemotherapy in treating patients with anaplastic or poorly differentiated thyroid cancer (Ongoing) | Metastatic thyroid gland carcinoma, Poorly differentiated thyroid gland carcinoma, Stage IVA/IVB/IVC thyroid gland anaplastic carcinoma AJCC v8, Gland anaplastic carcinoma, Unresectable thyroid gland carcinoma | Atezolizumab (anti-PDL1), Bevacizumab (anti-VEGFA), Cobimetinib (MEK inhibitor), Paclitaxel, Vemurafenib (B-Raf inhibitor), albumin nanoparticle-bound paclitaxel | NCT03181100 |
| 13 | Local consolidative therapy and Durvalumab for oligoprogressive and polyprogressive stage III NSCLC after chemoradiation and anti-PD-L1 therapy (Ongoing) | Stage III/IIIA/IIIB lung cancer AJCC v8 Stage III/IIIA/IIIB lung Non-Small Cell Cancer AJCC v7 |
Carboplatin, Durvalumab, Gemcitabine, Paclitaxel, Pemetrexed, albumin nanoparticle-bound paclitaxel | NCT04892953 |
| 14 | NBTXR3, Radiation therapy, Ipilimumab, and Nivolumab for the treatment of lung and/or liver metastases from solid malignancy (Ongoing) | Advanced malignant solid neoplasm, Meta- static malignant neo- plasm in the liver, Metastatic malignant neoplasm in the lung, Metastatic malignant solid neoplasm | Hafnium oxide-containing nanoparticles (NBTXR3), Ipilimumab (anti-CTLA4), Nivolumab along with radiation therapy | NCT05039632 |
| 15 | Durvalumab and Tremelimumab in combination with propranolol and chemotherapy for treatment of advanced hepato-pancreabiliary tumours (Ongoing) | Pancreatic Cancer, Hepatocellular Cancer, Biliary Tract Cancer, Cholangiocarcinoma | Durvalumab, Gemcitabine, Tremelimumab, Propranolol, Cisplatin, albumin nanoparticle-bound paclitaxel | NCT05451043 |
| 16 | Novel RNA-nanoparticle vaccine for the treatment of early melanoma recurrence following adjuvant anti-PD-1 antibody therapy (Ongoing) | Melanoma | Autologous total tumour mRNA loaded DOTAP liposome vaccine | NCT05264974 |
| 17 | CAR-T cell therapy in relapsed/refractory myeloma with extramedullary disease—an in vivo imaging and molecular monitoring study (CARAMEL) (Ongoing) | Extramedullary Myeloma | JNJ-68284528 (Cilta-cel)—B cell maturation antigen (BCMA) and 64Cu SPION dual PET-MR imaging agent | NCT05666700 |
| 18 | Split course adaptive radiation therapy with Pembrolizumab with/without chemotherapy for treating stage IV lung cancer (Ongoing) | Lung Non-Small Cell Carcinoma, Stage IV lung cancer AJCC v8 | Carboplatin, Fludeoxyglucose F-18, Pembrolizumab, Pemetrexed, albumin nanoparticle-bound paclitaxel along with radiation therapy, [18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan | NCT05501665 |